TriNet Prices Toward The Top Of Its 87% To 90% Cost Range As Inflation Persists

The CFO said lower pharmacy costs this year are not a lasting trend, and a one-time settlement gain in the second quarter will not repeat.

Share
TriNet Prices Toward The Top Of Its 87% To 90% Cost Range As Inflation Persists

TriNet, which provides outsourced HR services to small and medium-sized businesses, is pricing new and renewal business toward the high end of its 87% to 90% insurance cost ratio target, Chief Financial Officer Mala Murthy said on the company's third-quarter earnings call Thursday. She also warned that this year's cheaper-than-forecast pharmacy costs should not be read as a lasting change.

Pharmacy relief, with a warning

Murthy said pharma cost inflation has run below forecast this year, but TriNet does not view that as a long-term shift given the "probable future introduction of high-cost drugs." With specialty drugs and GLP-1 weight-loss drugs in the mix, she said, the company expects pharma trends to "reassert" to what it originally expected.

Third-quarter insurance cost ratio, the share of insurance revenue paid out in costs, came in at 89%, a one-point improvement from a year earlier. Insurance revenue fell 4% while insurance costs fell 5%. Health cost trends remain in the high single digits.

Murthy told analysts to remember a one-time, non-recurring benefit of about 50 basis points (half a percentage point) from a settlement in the second quarter when thinking about 2027. She said TriNet will not give a 2027 outlook for the ratio. With that benefit and better performance, she said, the company is now tracking to the low end of its full-year range, 88.5%.

Pricing at the top of the range

CEO Mike Simonds said healthcare cost inflation in the high single digits to low double digits has lasted "three plus years now," and it compounds. In that setting TriNet is targeting the top of its 87% to 90% range. If inflation moderates, he said, the company could price down toward the middle.

Simonds told a Stifel analyst that because TriNet takes on health-plan risk, it reprices a cohort of its book every quarter. Most peers that pass costs through get one annual renewal, he said. That lets TriNet move faster, including when inflation eventually eases, though he would not predict when.

For the fourth quarter, Murthy said the ratio is seasonally the highest because pooling deductibles reset. Guidance already allows for claims volatility, she said, which can cut either way.

Guidance and the quarter

TriNet left full-year guidance unchanged. Revenue is trending toward the bottom of its $4.75 billion to $4.9 billion range, while adjusted earnings per share are tracking at the high end of $4.50 to $5.10. Adjusted EBITDA margin is trending toward the high end of 8.5% to 9%.

Third-quarter revenue was $1.2 billion, down 5% from a year earlier, as ending worksite employees fell 11% to about 295,000 after a first-quarter repricing. Adjusted earnings were $0.94 per diluted share, and the company returned $33 million to shareholders through buybacks and dividends.

Simonds said new sales grew at a mid-single-digit rate in the quarter, and he expects high single digits in the fourth quarter.

Murthy said TriNet will not offer a 2027 view of its insurance cost ratio, leaving the pharmacy trend and the settlement benefit as the two items she asked analysts to keep in mind.

Sources

More on TriNet Group

All TriNet Group (TNET) coverage →